AU2011333772B2 - Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy - Google Patents

Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy Download PDF

Info

Publication number
AU2011333772B2
AU2011333772B2 AU2011333772A AU2011333772A AU2011333772B2 AU 2011333772 B2 AU2011333772 B2 AU 2011333772B2 AU 2011333772 A AU2011333772 A AU 2011333772A AU 2011333772 A AU2011333772 A AU 2011333772A AU 2011333772 B2 AU2011333772 B2 AU 2011333772B2
Authority
AU
Australia
Prior art keywords
compound
phenyl
sulfonamide
pyridine
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011333772A
Other languages
English (en)
Other versions
AU2011333772A1 (en
Inventor
Elisabeth Dupont-Passelaigue
Isabelle Le Roy
Christophe Pignier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2011333772A1 publication Critical patent/AU2011333772A1/en
Application granted granted Critical
Publication of AU2011333772B2 publication Critical patent/AU2011333772B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011333772A 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy Ceased AU2011333772B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR1059634 2010-11-23
PCT/EP2011/070736 WO2012069503A1 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy

Publications (2)

Publication Number Publication Date
AU2011333772A1 AU2011333772A1 (en) 2013-06-06
AU2011333772B2 true AU2011333772B2 (en) 2016-08-18

Family

ID=44246390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011333772A Ceased AU2011333772B2 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy

Country Status (19)

Country Link
US (2) US8846930B2 (enExample)
EP (1) EP2643318A1 (enExample)
JP (1) JP5837085B2 (enExample)
KR (1) KR101838326B1 (enExample)
CN (1) CN103209980B (enExample)
AR (1) AR083903A1 (enExample)
AU (1) AU2011333772B2 (enExample)
BR (1) BR112013012615A2 (enExample)
CA (1) CA2817531A1 (enExample)
FR (1) FR2967674B1 (enExample)
IL (1) IL226495A (enExample)
MA (1) MA34658B1 (enExample)
MX (1) MX352396B (enExample)
MY (1) MY168283A (enExample)
NZ (1) NZ610700A (enExample)
RU (1) RU2582995C2 (enExample)
TW (1) TWI576106B (enExample)
UA (1) UA109295C2 (enExample)
WO (1) WO2012069503A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
JP6272754B2 (ja) * 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
AU2012250690B2 (en) 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3057945A1 (en) * 2013-10-17 2016-08-24 Basf Se Process for preparing substituted isatoic acid anhydride compounds and derivatives thereof
WO2015095111A1 (en) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Diazepane orexin receptor antagonists
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
WO2018175707A1 (en) * 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用
TW202031645A (zh) * 2018-10-30 2020-09-01 丹麥商Ｈ 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
CN113200934B (zh) * 2021-05-18 2022-05-31 郑州大学 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用
CN113912595B (zh) * 2021-10-12 2024-03-15 中国药科大学 一类含有噻唑或噻二唑结构的化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130986A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149700A (en) * 1990-05-30 1992-09-22 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
RU2395502C2 (ru) * 2004-12-09 2010-07-27 Ф.Хоффманн-Ля Рош Аг Производные фенил-пиперазин метанона
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
WO2009055357A1 (en) * 2007-10-25 2009-04-30 Boehringer Ingelheim International Gmbh Diazepane compounds which modulate the cb2 receptor
CA2727780A1 (en) * 2008-06-13 2009-12-17 Bionomics Limited Novel potassium channel blockers and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN101503392B (zh) * 2009-03-31 2010-12-29 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
SG10201403696UA (en) * 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130986A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Also Published As

Publication number Publication date
TWI576106B (zh) 2017-04-01
FR2967674A1 (fr) 2012-05-25
KR101838326B1 (ko) 2018-03-13
US20140357624A1 (en) 2014-12-04
MA34658B1 (fr) 2013-11-02
CN103209980A (zh) 2013-07-17
FR2967674B1 (fr) 2012-12-14
JP5837085B2 (ja) 2015-12-24
US20130172326A1 (en) 2013-07-04
AU2011333772A1 (en) 2013-06-06
JP2014502268A (ja) 2014-01-30
AR083903A1 (es) 2013-04-10
TW201225951A (en) 2012-07-01
MY168283A (en) 2018-10-19
NZ610700A (en) 2014-12-24
MX2013005734A (es) 2013-08-01
BR112013012615A2 (pt) 2016-09-06
EP2643318A1 (en) 2013-10-02
MX352396B (es) 2017-11-22
IL226495A (en) 2017-06-29
RU2582995C2 (ru) 2016-04-27
WO2012069503A1 (en) 2012-05-31
CA2817531A1 (en) 2012-05-31
CN103209980B (zh) 2015-06-03
IL226495A0 (en) 2013-07-31
UA109295C2 (uk) 2015-08-10
RU2013126251A (ru) 2014-12-27
US9156834B2 (en) 2015-10-13
KR20130119943A (ko) 2013-11-01
HK1187345A1 (en) 2014-04-04
US8846930B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
JP5837085B2 (ja) ヘテロアリールスルホンアミド誘導体、それらの製造およびヒト治療におけるそれらの応用
KR100837420B1 (ko) 5-히드록시-인돌-3-카르복시산에스테르 유도체 및 이의용도
WO2011094890A1 (en) Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2887845C (en) Sodium channel blockers, preparation method thereof and use thereof
PT1024138E (pt) Derivados de pirazole
CN113811300A (zh) Tead转录因子的新型小分子抑制剂
CN102558149A (zh) 嘧啶衍生物、及其制法和药物组合物与用途
CN102112453A (zh) 新的钾通道阻断剂及其用途
EP1783116B1 (en) 2-phenylpyridine derivative
CN102341385A (zh) 能够抑制前列腺素d合酶的哌嗪化合物
TW201443025A (zh) 化學化合物
AU2007298540A1 (en) 3 -amino- pyridine derivatives for the treatment of metabolic disorders
EP1783124A1 (en) 2-phenylthiophene derivative
CA2859586C (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
JP6671382B2 (ja) 特に糖尿病の治療に有用である２−（１，２，４−トリアゾール−３−イルスルファニル）−ｎ−１，３，４−チアジアゾール−２−イルアセトアミドの誘導体
SG178043A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
OA16434A (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy.
CN101648919A (zh) 3-取代水杨酰胺化合物、及其制法和药物组合物与用途
HK1187345B (en) Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
CN102432592A (zh) 具有抗肿瘤作用的芳基脲衍生物及其制备方法
HK40039623B (zh) 用於治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired